公开(公告)号：EP1676590A4

公开(公告)日：2007-08-15

申请号：EP04792438

申请日：2004-10-15

Applicant: NEW IND RES ORGANIZATION

Inventor： HAMADA KATSUYUKI ,  GOTO AKINOBU ,  SHIRAKAWA TOSHIRO

IPC: A61K48/00 ,  A61K31/409 ,  A61K33/26 ,  A61K35/12 ,  A61K35/76 ,  A61P35/00 ,  C07K14/475 ,  C12N15/00 ,  C12N15/85 ,  C12N15/861

CPC classification number: C12N7/00 ,  A61K31/409 ,  A61K35/761 ,  A61K38/193 ,  A61K48/0058 ,  A61K2039/5256 ,  A61K2039/57 ,  C07K14/475 ,  C12N15/85 ,  C12N15/86 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/85 ,  A61K2300/00

Abstract: An oncogene therapeutic drug which contains a carrier cell having been infected with an oncolytic virus so as to treat a tumor cell with the virus within the living body. As the carrier cell, any of an A549 cell, a 293 cell, an SW626 cell and an HT-3 cell showing a potent antitumor effect is used. Because of using such a cell having a high antitumor effect both in vitro and in vivo as the carrier cell, an enhanced antitumor effect can be established compared with conventional carrier cells.

Abstract translation: 一种癌基因治疗药，它含有一种已被溶瘤病毒感染的载体细胞，以便在生物体内用病毒治疗肿瘤细胞。 作为载体细胞，使用显示有效的抗肿瘤作用的A549细胞，293细胞，SW626细胞和HT-3细胞中的任一种。 由于使用这种体外和体内抗肿瘤效果高的细胞作为载体细胞，因此与常规载体细胞相比，可以建立增强的抗肿瘤效果。

公开(公告)号：EP1676589A4

公开(公告)日：2007-08-15

申请号：EP04792437

申请日：2004-10-15

Applicant: NEW IND RES ORGANIZATION

Inventor： HAMADA KATSUYUKI ,  GOTO AKINOBU ,  SHIRAKAWA TOSHIRO

IPC: A61K48/00 ,  A61K31/409 ,  A61K33/26 ,  A61K35/12 ,  A61K35/76 ,  A61P35/00 ,  C07K14/475 ,  C12N15/00 ,  C12N15/85 ,  C12N15/861

CPC classification number: C12N7/00 ,  A61K31/409 ,  A61K35/761 ,  A61K38/193 ,  A61K48/0058 ,  A61K2039/5256 ,  A61K2039/57 ,  C07K14/475 ,  C12N15/85 ,  C12N15/86 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/85 ,  A61K2300/00

Abstract: An oncogene therapeutic drug which comprises a combination of a virus for an immunological treatment to be administered for inducing a CTL reaction within the living body with a carrier cell having been infected with an oncolytic virus before administration so as to treat a tumor cell with the virus within the living body. As the carrier cell, use can be made of, for example, an A549 cell. As the virus for an immunological treatment, use can be made of, for example, a non-proliferative adenovirus having been inactivated by UV irradiation. As the oncolytic virus, use can be made of, for example, a proliferative adenovirus having a tumor-specific promoter.

公开(公告)号：CA2542335A1

公开(公告)日：2005-04-28

申请号：CA2542335

申请日：2004-10-15

Applicant: NEW IND RES ORGANIZATION

Inventor： SHIRAKAWA TOSHIRO ,  HAMADA KATSUYUKI ,  GOTO AKINOBU

IPC: A61K48/00 ,  A61K31/409 ,  A61K33/26 ,  A61K35/12 ,  A61K35/13 ,  A61K35/76 ,  A61K35/761 ,  A61K35/763 ,  A61K35/765 ,  A61K35/766 ,  A61K39/12 ,  A61K47/42 ,  A61P35/00 ,  C07K14/475 ,  C12N15/00 ,  C12N15/85 ,  C12N15/861

Abstract: An oncogene therapeutic drug which comprises a combination of a virus for an immunological treatment to be administered for inducing a CTL reaction withi n the living bodywith a carrier cell having been infected with an oncolytic virus before administration so as to treat a tumor cell with the virus withi n the living body. As the carrier cell, use can be made of, for example, an A5 49 cell. As the virus for an immunological treatment, use can be made of, for example, a non-proliferative adenovirus having been inactivated by UV irradiation. As the oncolytic virus, use can be made of, for example, a proliferative adenovirus having a tumor-specific promoter.

公开(公告)号：CA2542337A1

公开(公告)日：2005-04-28

申请号：CA2542337

申请日：2004-10-15

Applicant: NEW IND RES ORGANIZATION

Inventor： SHIRAKAWA TOSHIRO ,  HAMADA KATSUYUKI ,  GOTO AKINOBU

IPC: A61K48/00 ,  A61K31/409 ,  A61K33/26 ,  A61K35/12 ,  A61K35/13 ,  A61K35/76 ,  A61K35/761 ,  A61K35/763 ,  A61K35/765 ,  A61K35/766 ,  A61K39/12 ,  A61K47/42 ,  A61P35/00 ,  C07K14/475 ,  C12N15/00 ,  C12N15/85 ,  C12N15/861

Abstract: An oncogene therapeutic drug which contains a carrier cell having been infected with an oncolytic virus so as to treat a tumor cell with the virus within the living body. As the carrier cell, any of an A549 cell, a 293 cell , an SW626 cell and an HT-3 cell showing a potent antitumor effect is used. Because of using such a cell having a high antitumor effect both in vitro an d in vivo as the carrier cell, an enhanced antitumor effect can be established compared with conventional carrier cells.